Brief: Orchard Therapeutics Announces Encouraging Update From Proof-Of-Concept Study Of OTL-203 For The Treatment Of MPS-I

Orchard Therapeutics

04/09/2019 12:29

Sept 4 (Reuters) - Orchard Therapeutics PLC  ORTX.O :
    * ORCHARD THERAPEUTICS ANNOUNCES ENCOURAGING UPDATE FROM
PROOF-OF-CONCEPT STUDY OF OTL-203 FOR THE TREATMENT OF
MUCOPOLYSACCHARIDOSIS TYPE I (MPS-I)
    * ORCHARD THERAPEUTICS PLC - EVIDENCE OF ENGRAFTMENT AND
PERIPHERAL BLOOD ALPHA-L-IDURONIDASE (IDUA) ENZYME
OVEREXPRESSION ACROSS COHORT
    * ORCHARD THERAPEUTICS PLC - SIX OF EIGHT PATIENTS TREATED
TO DATE
WITH FOLLOW-UP OUT TO 12 MONTHS IN FIRST PATIENT TO RECEIVE
TREATMENT
    * ORCHARD THERAPEUTICS PLC - PROOF-OF-CONCEPT STUDY IS
ONGOING AND
EXPECTED TO ENROLL EIGHT PATIENTS BY FIRST HALF OF 2020
    * ORCHARD THERAPEUTICS PLC - TREATMENT WITH OTL-203
DEMONSTRATED:
GENE THERAPY AND SELECTED CONDITIONING REGIME WERE
WELL-TOLERATED
    * ORCHARD THERAPEUTICS PLC - PRELIMINARY CLINICAL EVALUATION
SHOWED SIGNS OF RESUMED GROWTH, IMPROVED MOTOR SKILLS AND A
STABLE COGNITIVE SCORE

Source text for Eikon:  ID:nGNX6fqdvV 
Further company coverage:  ORTX.O 

 (Reuters.Briefs@thomsonreuters.com)